U.S. patent office rules against Amgen Humira challenge

(Reuters) - U.S. patent officials on Thursday denied petitions by Amgen to review two formulation patents on AbbVie's Humira, a potential setback in Amgen efforts to market a biosimilar version of the world's top-selling prescription medicine.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro